Oncology Archives - WuXi Biology

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...

Targeting ER Mutations and Drug Resistance

Targeting ER Mutations and Drug Resistance: R&D Strategies and Comprehensive Preclinical Evaluation of Novel ER Degraders Introduction Estrogen receptor (ER)-positive...

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

Mechanistic Profiling of ADC-resistant Cancer Cell Lines

Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...

Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...